- Home
- IBCP vs ATXS Comparison
IBCP vs ATXS Comparison
Compare IBCP & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBCP
- ATXS
- Stock Information
- Founded
- IBCP 1864
- ATXS 2008
- Country
- IBCP United States
- ATXS United States
- Employees
- IBCP N/A
- ATXS N/A
- Industry
- IBCP Major Banks
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- IBCP Finance
- ATXS Health Care
- Exchange
- IBCP Nasdaq
- ATXS Nasdaq
- Market Cap
- IBCP 795.2M
- ATXS 669.8M
- IPO Year
- IBCP N/A
- ATXS 2015
- Fundamental
- Price
- IBCP $37.74
- ATXS $9.37
- Analyst Decision
- IBCP Hold
- ATXS Strong Buy
- Analyst Count
- IBCP 3
- ATXS 5
- Target Price
- IBCP $32.17
- ATXS $25.60
- AVG Volume (30 Days)
- IBCP 111.9K
- ATXS 219.2K
- Earning Date
- IBCP 10-24-2024
- ATXS 11-13-2024
- Dividend Yield
- IBCP 2.54%
- ATXS N/A
- EPS Growth
- IBCP 3.52
- ATXS N/A
- EPS
- IBCP 2.94
- ATXS N/A
- Revenue
- IBCP $208,212,000.00
- ATXS N/A
- Revenue This Year
- IBCP N/A
- ATXS N/A
- Revenue Next Year
- IBCP $5.96
- ATXS N/A
- P/E Ratio
- IBCP $12.84
- ATXS N/A
- Revenue Growth
- IBCP 3.25
- ATXS N/A
- 52 Week Low
- IBCP $20.50
- ATXS $4.26
- 52 Week High
- IBCP $39.52
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- IBCP 63.08
- ATXS 30.44
- Support Level
- IBCP $31.79
- ATXS $11.40
- Resistance Level
- IBCP $39.52
- ATXS $11.75
- Average True Range (ATR)
- IBCP 1.20
- ATXS 0.75
- MACD
- IBCP 0.38
- ATXS -0.23
- Stochastic Oscillator
- IBCP 76.97
- ATXS 7.64
About IBCP Independent Bank Corporation
Independent Bank Corp (Ionia MI) operates as a commercial bank. It offers a broad range of banking services to individuals and businesses, including checking and savings accounts, commercial lending, direct and indirect consumer financing, mortgage lending, and safe deposit box services. It also provides internet and mobile banking capabilities to its customers.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.